Literature DB >> 15648180

Application of genetics to the prevention of colorectal cancer.

John L Hopper1.   

Abstract

A first-degree relative of an individual with colorectal cancer is on average at about a twofold increased risk. This could not occur without there being strong underlying risk factors that are correlated in relatives. About 90% of colorectal cases occur in people who are above median familial/genetic risk, so there is great potential to use genetics to prevent colorectal cancer. Two rare inherited syndromes have been identified: familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). The former appears to be mostly due to mutations in the APC gene, and the latter to mutations in mismatch repair (MMR) genes, so it would be better named as hereditary mismatch repair deficiency (HMRDS). By fully characterising a population-based series of early-onset cases, we have shown that MMR gene mutation carriers and their relatives can be more efficiently identified by characterising the tumours of early-onset cases, independently of their cancer family history, using immunohistochemistry (IHC)-not microsatellite instability (MSI) testing. This identifies the specific MMR gene likely to be involved, reducing the costs of mutation testing. Identification of genetically susceptible individuals using the tumour phenotype of affecteds, rather than family cancer history, could become the standard approach of cancer genetic services in the twenty-first century, and could lead to cancer prevention in individuals who are at a high genetic risk when young. There is an urgent need for research on the efficacy and optimisation of surveillance procedures in these high-risk individuals, and identification of the environmental, lifestyle and other genetic factors that exacerbate, or ameliorate, risk in mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15648180     DOI: 10.1007/3-540-26980-0_2

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  6 in total

1.  Determining the frequency of de novo germline mutations in DNA mismatch repair genes.

Authors:  Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor
Journal:  J Med Genet       Date:  2011-06-02       Impact factor: 6.318

Review 2.  Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer.

Authors:  Mark A Jenkins; Melissa C Southey; Graham G Giles; John L Hopper
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

Review 3.  Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis.

Authors:  Driss Ait Ouakrim; Trevor Lockett; Alex Boussioutas; John L Hopper; Mark A Jenkins
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

4.  Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Authors:  Driss Ait Ouakrim; Seyedeh Ghazaleh Dashti; Rowena Chau; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Barbara Leggett; Finlay A Macrae; Dennis J Ahnen; Graham Casey; Steven Gallinger; Robert W Haile; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  J Natl Cancer Inst       Date:  2015-06-24       Impact factor: 13.506

5.  Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome.

Authors:  Rowena Chau; Seyedeh Ghazaleh Dashti; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Finlay A Macrae; Alex Boussioutas; Susan Parry; Jane C Figueiredo; A Joan Levine; Dennis J Ahnen; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  Int J Epidemiol       Date:  2016-04-10       Impact factor: 7.196

6.  Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome.

Authors:  S Ghazaleh Dashti; Wing Yan Li; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Finlay A Macrae; Graham G Giles; Sheetal Hardikar; Xinwei Hua; Stephen N Thibodeau; Jane C Figueiredo; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John D Potter; Noralane M Lindor; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  Br J Cancer       Date:  2019-09-25       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.